产品搜索 抗体高级搜索

首页 > 产品列表 > 一抗 > 细胞生物学

Anti-Human DR4(NT)

产品编号:D250

产品描述:Anti-Human DR4(NT)

反应种属:human

实验方法:WB

标记:

规格:0.1mg

供应商:leinco

价格(RMB):5370.00

订购:订购

说明书:

Rabbit Anti-Human TNF-Related Apoptosis Inducing Ligand Receptor-1 (TRAIL R-1)
Purified No Carrier Protein
(TNFRSF10A, APO2, CD261, DR4, MGC9365)
Polyclonal Antibody

Prod. No.: D250
Host:         Rabbit
Conc.:      0.5 mg/ml
Pkg. Size: 1 mg, 0.1 mg, 0.5 mg
Storage:     2-8°C

Description
Specificity:
Rabbit Anti-Human TNF-Related Apoptosis Inducing Ligand Receptor-1 (TRAIL R-1) recognizes Human TRAIL R-1. This polyclonal antibody was purified using affinity chromatography.

Background:

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 1 (TRAIL-R1) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2

Known Species Cross Reactivity: Hu+

Immunogen
TRAIL Receptor-1 (NT) Blocking Peptide (Leinco Prod. No.: D278)
Blocking Peptide
TRAIL Receptor-1 (NT) Blocking Peptide (Leinco Prod. No.: D278)
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Stability
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Reported Applications
WB

References
1. Nam Jin Yoo et al. (2001) Oncogene 20: 399
2. Jürgen Eberle et al. (2005) J Investigative Dermatol. 125: 1010

Related Products
TRAIL Receptor-1 (NT) Blocking Peptide (Leinco Prod. No.: D278)
TRAIL Receptor-1 (CT) Blocking Peptide (Leinco Prod. No.: D277)
Anti-Human TRAIL Receptor-1 (CT) (Leinco Prod. No.: D249)

Products are for research use only. Not for use in diagnostic or therapeutic procedures.